The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update
-
- M. Maurer
- Department of Dermatology and Allergy Charité—Universitätsmedizin Berlin Berlin Germany
-
- M. Magerl
- Department of Dermatology and Allergy Charité—Universitätsmedizin Berlin Berlin Germany
-
- I. Ansotegui
- Department of Allergy and Immunology Hospital Quironsalud Bizkaia Bilbao Spain
-
- E. Aygören‐Pürsün
- Center for Children and Adolescents University Hospital Frankfurt Frankfurt Germany
-
- S. Betschel
- Division of Clinical Immunology and Allergy St. Michael's Hospital University of Toronto Toronto ON Canada
-
- K. Bork
- Department of Dermatology Johannes Gutenberg University Mainz Mainz Germany
-
- T. Bowen
- Department of Medicine and Pediatrics University of Calgary Calgary AB Canada
-
- H. Balle Boysen
- HAEi Lausanne Switzerland
-
- H. Farkas
- Hungarian Angioedema Center 3rd Department of Internal Medicine Semmelweis University Budapest Hungary
-
- A. S. Grumach
- Clinical Immunology Faculdade de Medicina ABC São Paulo Brazil
-
- M. Hide
- Department of Dermatology Hiroshima University Hiroshima Japan
-
- C. Katelaris
- Department of Medicine Campbelltown Hospital and Western Sydney University Sydney NSW Australia
-
- R. Lockey
- Department of Internal Medicine University of South Florida Morsani College of Medicine Tampa FL USA
-
- H. Longhurst
- Department of Clinical Biochemistry and Immunology Addenbrooke's Hospital Cambridge University Hospitals NHS Foundation Trust UK
-
- W. R. Lumry
- Department of Internal Medicine Allergy/Immunology Division Southwestern Medical School University of Texas Dallas TX USA
-
- I. Martinez‐Saguer
- Hemophilia Centre Rhine Main Moerfelden‐Walldorf Germany
-
- D. Moldovan
- University of Medicine and Pharmacy Tîrgu Mures Romania
-
- A. Nast
- Berlin Institute of Health Department of Dermatology, Venereology und Allergy Division of Evidence based Medicine (dEBM) Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin Charité—Universitätsmedizin Berlin Berlin Germany
-
- R. Pawankar
- Department of Pediatrics Nippon Medical School Tokyo Japan
-
- P. Potter
- Department of Medicine University of Cape Town Cape Town South Africa
-
- M. Riedl
- Department of Medicine University of California—San Diego La Jolla CA USA
-
- B. Ritchie
- Division of Hematology University of Alberta Edmonton AB Canada
-
- L. Rosenwasser
- Allergy and Immunology Department University of Missouri at Kansas City School of Medicine Kansas City MO USA
-
- M. Sánchez‐Borges
- Allergy and Clinical Immunology Department Centro Medico Docente La Trinidad Caracas Venezuela
-
- Y. Zhi
- Department of Allergy Peking Union Medical College Hospital and Chinese Academy of Medical Sciences Beijing China
-
- B. Zuraw
- Department of Medicine University of California—San Diego La Jolla CA USA
-
- T. Craig
- Department of Medicine and Pediatrics Penn State University Hershey PA USA
Description
<jats:title>Abstract</jats:title><jats:p>Hereditary Angioedema (<jats:styled-content style="fixed-case">HAE</jats:styled-content>) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for <jats:styled-content style="fixed-case">HAE</jats:styled-content> provides up‐to‐date consensus recommendations for the management of <jats:styled-content style="fixed-case">HAE</jats:styled-content>. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of <jats:styled-content style="fixed-case">HAE</jats:styled-content> with deficient C1‐inhibitor (type 1) and <jats:styled-content style="fixed-case">HAE</jats:styled-content> with dysfunctional C1‐inhibitor (type 2). The key clinical questions covered by these recommendations are: (1) How should <jats:styled-content style="fixed-case">HAE</jats:styled-content>‐1/2 be defined and classified?, (2) How should <jats:styled-content style="fixed-case">HAE</jats:styled-content>‐1/2 be diagnosed?, (3) Should <jats:styled-content style="fixed-case">HAE</jats:styled-content>‐1/2 patients receive prophylactic and/or on‐demand treatment and what treatment options should be used?, (4) Should <jats:styled-content style="fixed-case">HAE</jats:styled-content>‐1/2 management be different for special <jats:styled-content style="fixed-case">HAE</jats:styled-content>‐1/2 patient groups such as pregnant/lactating women or children?, and (5) Should <jats:styled-content style="fixed-case">HAE</jats:styled-content>‐1/2 management incorporate self‐administration of therapies and patient support measures?</jats:p>
Journal
-
- Allergy
-
Allergy 73 (8), 1575-1596, 2018-03-12
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1360004235469711360
-
- ISSN
- 13989995
- 01054538
-
- Data Source
-
- Crossref
- KAKEN